company background image
A017180 logo

MYUNGMOON PharmLtd KOSE:A017180 Stock Report

Last Price

₩1.82k

Market Cap

₩61.0b

7D

-4.7%

1Y

-17.1%

Updated

24 Dec, 2024

Data

Company Financials

MYUNGMOON Pharm co.,Ltd

KOSE:A017180 Stock Report

Market Cap: ₩61.0b

A017180 Stock Overview

Engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. More details

A017180 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

MYUNGMOON Pharm co.,Ltd Competitors

Price History & Performance

Summary of share price highs, lows and changes for MYUNGMOON PharmLtd
Historical stock prices
Current Share Price₩1,824.00
52 Week High₩2,970.00
52 Week Low₩1,599.00
Beta0.18
1 Month Change-3.29%
3 Month Change-18.93%
1 Year Change-17.09%
3 Year Change-59.74%
5 Year Change-62.58%
Change since IPO-40.53%

Recent News & Updates

Health Check: How Prudently Does MYUNGMOON PharmLtd (KRX:017180) Use Debt?

Dec 16
Health Check: How Prudently Does MYUNGMOON PharmLtd (KRX:017180) Use Debt?

Is MYUNGMOON PharmLtd (KRX:017180) Weighed On By Its Debt Load?

Sep 06
Is MYUNGMOON PharmLtd (KRX:017180) Weighed On By Its Debt Load?

MYUNGMOON Pharm co.,Ltd's (KRX:017180) 35% Share Price Surge Not Quite Adding Up

Jul 26
MYUNGMOON Pharm co.,Ltd's (KRX:017180) 35% Share Price Surge Not Quite Adding Up

Recent updates

Health Check: How Prudently Does MYUNGMOON PharmLtd (KRX:017180) Use Debt?

Dec 16
Health Check: How Prudently Does MYUNGMOON PharmLtd (KRX:017180) Use Debt?

Is MYUNGMOON PharmLtd (KRX:017180) Weighed On By Its Debt Load?

Sep 06
Is MYUNGMOON PharmLtd (KRX:017180) Weighed On By Its Debt Load?

MYUNGMOON Pharm co.,Ltd's (KRX:017180) 35% Share Price Surge Not Quite Adding Up

Jul 26
MYUNGMOON Pharm co.,Ltd's (KRX:017180) 35% Share Price Surge Not Quite Adding Up

MYUNGMOON PharmLtd (KRX:017180) Has No Shortage Of Debt

Mar 21
MYUNGMOON PharmLtd (KRX:017180) Has No Shortage Of Debt

Does MYUNGMOON PharmLtd (KRX:017180) Have A Healthy Balance Sheet?

Mar 31
Does MYUNGMOON PharmLtd (KRX:017180) Have A Healthy Balance Sheet?

Introducing MYUNGMOON PharmLtd (KRX:017180), A Stock That Climbed 77% In The Last Five Years

Feb 06
Introducing MYUNGMOON PharmLtd (KRX:017180), A Stock That Climbed 77% In The Last Five Years

Does Myungmoon Pharm (KRX:017180) Have A Healthy Balance Sheet?

Dec 15
Does Myungmoon Pharm (KRX:017180) Have A Healthy Balance Sheet?

Shareholder Returns

A017180KR PharmaceuticalsKR Market
7D-4.7%1.0%-0.9%
1Y-17.1%2.4%-9.0%

Return vs Industry: A017180 underperformed the KR Pharmaceuticals industry which returned 4.3% over the past year.

Return vs Market: A017180 underperformed the KR Market which returned -9% over the past year.

Price Volatility

Is A017180's price volatile compared to industry and market?
A017180 volatility
A017180 Average Weekly Movement6.6%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.7%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A017180 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A017180's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1983282Kyu-Huok Leewww.mmpharm.co.kr

MYUNGMOON Pharm co.,Ltd engages in the research, development, production, distribution, and sale of pharmaceuticals in South Korea and internationally. It offers prescription drugs, including anti osteoarthritis, anti-inflammatory analgesics, antiphlogistic enzymes, muscle relaxant, anti rheumarthritis, antibiotics and antifungal, respiratory agents, GI therapeutics, circulation agents, anti-hypertension agents, antidiabetic drugs, narcotics, anesthetic agents, central nervous system products, female hormone products, osteoporotic therapeutics, urogentital agents, adrenocortical hormone products, oncology agents, other preparations, and anti-obesity agents for pharmacotherapy. The company also provides OTC products, such as antinausants, genitourinary system products, anti gum disease products, hepatics, parasiticides, cathartic, antidiarrheal agents, digestive system products, multiple vitamin products, eye nutrition products, eye drops, blood circulation products, circulatory solvents, skin external preparations, and topical analgesic products.

MYUNGMOON Pharm co.,Ltd Fundamentals Summary

How do MYUNGMOON PharmLtd's earnings and revenue compare to its market cap?
A017180 fundamental statistics
Market cap₩60.97b
Earnings (TTM)-₩7.57b
Revenue (TTM)₩180.14b

0.3x

P/S Ratio

-8.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A017180 income statement (TTM)
Revenue₩180.14b
Cost of Revenue₩80.09b
Gross Profit₩100.05b
Other Expenses₩107.63b
Earnings-₩7.57b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-226.58
Gross Margin55.54%
Net Profit Margin-4.20%
Debt/Equity Ratio105.6%

How did A017180 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:50
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MYUNGMOON Pharm co.,Ltd is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution